CBT Pharmaceuticals and CrystalGenomics Announce Partnership for Co-development of Global Immuno-Oncology Therapy
CBT-501 is a novel IgG4 humanized monoclonal antibody against the Programmable Death-1 (PD-1) membrane receptor on immune cells. It has a comparable efficacy profile in in vitro and in vivo studies to the marketed anti-PD-1 antibodies, nivolumab and pembrolizumab, and has a favorable profile with very low antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) activity. CBT-501 is under evaluation in two Phase I trials designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics in patients with advanced solid tumors, recurrent or refractory to standard of care therapies (NCT03053466, NCT03374007).
CG200745, is a novel pan-HDAC inhibitor currently in Phase II clinical study for pancreatic cancer (NCT02737228) and Phase Ib for myelodysplastic syndrome (NCT02737462) in Korea. CG200745 has the potential to be a best-in-class compound based on preclinical and interim Phase Ib/II clinical data and is projected to have superior pharmacokinetic (PK) profile, pharmacodynamic (PD) response, efficacy, and safety, over other HDAC inhibitors. In its first-in-human study of the toxicity, PK and PD in patients with refractory solid malignancies, stable disease was observed in 57.1% of the subjects treated with CG200745 as monotherapy and excellent safety profile was observed as the maximum tolerated dose (MTD) was never reached (NCT01226407).
About CBT Pharmaceuticals
CBT Pharmaceuticals, Inc. is an innovative biopharmaceutical company committed to becoming a global leader in the discovery and development of oncology combination therapies that harness the immune system and target specific molecular pathways to tame cancer. The company’s existing pipeline of five development-stage assets include three novel humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and two targeted therapies against uncontrolled growth signaling pathways. For more information, please visit www.cbtpharma.com and follow us on Twitter @CBTpharma.
CrystalGenomics, Inc. is a commercial stage biopharmaceutical company focused in the structure-based drug discovery and development of novel therapeutics in unmet medical need areas of inflammation, oncology, and infectious disease. In addition to several drug programs in the research and development pipeline, the company has a drug on the market for osteoarthritis and has recently added commercial manufacturing, sales and marketing capabilities through multiple acquisitions. CrystalGenomics, Inc. is listed on KOSDAQ (083790). www.cgxinc.com or www.crystalgenomics.com.
Source: CBT Pharmaceuticals, Inc.